| 名稱 | Avasimibe |
| 描述 | Avasimibe (PD-148515) is an orally bioavailable inhibitor of acyl-Coenzyme A: cholesterol acyltransferase (ACAT, IC50: 3.3 μM) that prevents cholesterol deposition in the arterial wall. It also inhibits human P450 isoenzymes CYP2C9/1A2/2C19 (IC50: 2.9/13.9/26.5 μM). |
| 細胞實驗 | For foam cell formation, the growth medium (RPMI medium containing 10% human serum) is aspirated and the BMMs are rinsed four times with RPMI medium, and then HMMs are exposed to RPMI medium containing bovine serum albumin (BSA, 0.2%) and dimethylsulfoxide (DMSO, 0.2%, vehicle for CI-1011) (control medium) with and without agacLDL (100 μg protein/ml) and CI-1011 (1 μg/ml) for 48 hours. For cholesterol efflux experiments, HMMs are preincubated with ag-acLDL (100 μg protein/ml) for 24h, and then exposed to control RPMI medium with and without HDL (100 μg protein/ml), CI-1011 (2 μg/ml) or HDL plus CI-1011 (2 μg/ml) for 24–48 hours. Additionally, the appearance of [14C]FC in the medium is monitored by first preincubating HMMs with RPMI medium containing ag-acLDL (100 μg protein/ml) radiolabeled with [4-14C]FC (0.5 μCi/ml) in an ethanolic spritz (final concentration, 0.1%) for 24 h. The medium is removed, cells rinsed three times with RPMI medium, and then cells are exposed to control RPMI medium with and without CI-1011 (1–10 μg/ml) for 4–48 h. At each time point, the medium is aspirated and centrifuged to pellet nonadherent cells. The appearance of [14C]FC in the medium is measured by liquid scintillation spectroscopy. Cellular lipids are extracted using hexane:isopropanol (3:2, v/v) for 1 h. The distribution of cellular radiolabeled cholesterol is measured by subjecting an aliquot of the cell extract and FC and EC standards to thin layer chromatography using petroleum ether:hexane:glacial acetic acid solvent system (85:15:2, v/v). The percent FC efflux is calculated as: medium [14C]FC dpm/ cell [14C] dpm×100. FC and TC mass are quantified by gas liquid chromatography using stigmasterol (1 mg/ml) as an internal standard. EC mass is calculated as the difference between TC and FC, and all values are normalized to cell protein. The MBC is de?ned as the lowest concentration that exhibited 99.9% or more reduction of the numbers of colonies compared with the cfu in the initial inoculum. (Only for Reference) |
| 激酶實驗 | P450 Inhibition Studies: Pooled human liver microsomes (HLM) from at least 15 donors are used for all inhibition assays. For IC50 determinations, the substrate probes are used at their approximate in vitro Km values. All incubations are performed with 100 mM potassium phosphate buffer (pH 7.4) and 1 mM NADPH. For CYP1A2 inhibition study, incubations are performed in a total volume of 0.5 ml, in duplicates with 0.1 mg/ml HLM, 30 μM phenacetin, 1 mM NADPH, and in the presence of avasimibe (0, 0.3, 0.75, 1.5, 3, 7.5, 15, 30, and 40 μM in 50 mM) in a potassium phosphate buffer at pH 7.4. After preincubation at 37 °C for 7 min, NADPH is added to initiate the enzyme reaction. The reaction mixture is quenched with 500 μl of ice-cold 100 ng/ml paracetamol-D4/CH3CN after 25 min. The standards (4-acetamidophenol, singlet) and quality controls (triplicates for low, medium, and high) are prepared at room temperature. After mixing, 0.2 ml of the samples is transferred to another plate and submitted for LC/MS/MS analysis after centrifugation at 3000 rpm for 10 min. A Supelco Discovery Amide C16, 100 × 2.1 mm (5-μm particle size) column (Supelco, Bellefonte, PA) is used. The mobile phase is isocratic, 40:60 [acetonitrile/formic acid, 0.1% (v/v)] at 0.2 ml/min. |
| 體外活性 | Avasimibe通過降低低密度脂蛋而降低總膽固醇.在9只健康雄性猴子體內(nèi),Avasimibe明顯降低脂蛋白(a)和總膽固醇水平,Avasimibe（30 mg/kg/day,p.o.）飼喂3周,可使總膽固醇和脂蛋白(a)水平分別降低至對照水平的73和68%. |
| 體內(nèi)活性 | 在HepG2 細胞中溫育24 h,Avasimibe（0.01/1/10 μM）可使分泌到培養(yǎng)基中的ApoB分別降低 25%,27%和43%。在人類單核細胞衍生的巨噬細胞中,通過抑制泡沫細胞形成期低密度脂蛋結(jié)合和降低清除劑受體數(shù),Avasimibe（1μg/ml）可降低酯化膽固醇和總膽固醇。Avasimibe（2μg/ml）與低密度脂蛋白（10μg/ml）預溫育,可使膽固醇從HMM泡沫細胞中的外排增強。Avasimibe是通過增強細胞內(nèi)ApoB降解來降低ApoB分泌,但不影響其ApoB合成。 在IC-21巨噬細胞中,Avasimibe抑制 ACTC（IC50：3.3 μM）。 在膠質(zhì)瘤細胞中,Avasimibe對膽固醇酯的合成和ACAT-1 表達有抑制作用。通過誘導細胞周期停滯和caspase-8/3激活引起的凋亡,Avasimibe可抑制膠質(zhì)瘤細胞生長。Avasimibe劑量依賴性抑制原代猴肝臟細胞培養(yǎng)基中的脂蛋白(a)累積（11.9% -31.3%）,這與 ApoA降低有關(guān)。 |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 100 mg/mL (199.31 mM)
Ethanol : 2 mg/mL (4 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| 關(guān)鍵字 | Inhibitor | ACAT2 | CI1011 | PD148515 | Diacylglycerol acyltransferase | active | mono- acylglycerol acyltransferase | Diglyceride acyltransferase | SOAT | acyl-CoA:cholesterol acyltransferase | ACAT1 | CI 1011 | PD 148515 | Avasimibe | orally | ACAT | Acyltransferase | inhibit |
| 相關(guān)產(chǎn)品 | Naringin | 1-Aminobenzotriazole | Fenofibrate | Tauroursodeoxycholate | Cyclandelate | Naringenin | Apigenin | 1-Ethynylnaphthalene | Tebuconazole | Diflubenzuron |
| 相關(guān)庫 | 抑制劑庫 | 抗癌活性化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | ReFRAME 相關(guān)化合物庫 | 代謝化合物庫 | 抗衰老化合物庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |